The webinar will focus upon the common issues which might delay the IND submission or pre-IND interaction with FDA. We will discuss how to design your in-vitro or in-vivo studies timely and effectively to overcome these issues, with a view toward current regulatory guidelines and the expectations of regulatory agencies.
In this webinar you’ll learn:
Common roadblocks & mitigation strategies
Designing studies effectively and efficiently
Compiling the IND package & interactions with FDA
Who should attend?
Scientists, Postdoctoral fellows, PIs (Cell & Molecular Biologist)
CGT start-up aspirants
Vibhor Gupta, Ph.D.
(Presenter) Director of Business Operations, Cell and Gene Therapy Absorption Systems View Biography
(Moderator) Editor-in-Chief, American Pharmaceutical Review